Updated Aug 5, 2026
/D-Wave Quantum reports 99.9% two-qubit fidelity in Nature paper, targeting fault-tolerant system by 2032/Conestoga Microcap opens stakes in NCNO and NPKI, exits NABL and PL in second-quarter moves/SpaceX falls 12% as AI spending surge rattles investors despite Musk revenue pull-forward/Missouri trio charged over alleged Bitcoin kidnapping plot/Japan cabinet secretary affirms Bank of Japan's authority over monetary policy tools/Hut 8 shares slip on mild Q2 revenue miss as AI data center pipeline expands/D-Wave Quantum reports 99.9% two-qubit fidelity in Nature paper, targeting fault-tolerant system by 2032/Conestoga Microcap opens stakes in NCNO and NPKI, exits NABL and PL in second-quarter moves/SpaceX falls 12% as AI spending surge rattles investors despite Musk revenue pull-forward/Missouri trio charged over alleged Bitcoin kidnapping plot/Japan cabinet secretary affirms Bank of Japan's authority over monetary policy tools/Hut 8 shares slip on mild Q2 revenue miss as AI data center pipeline expands

J&J Bets on Cancer Over Obesity as FDA Clears GSK Antibiotic for Drug-Resistant Infections

Johnson & Johnson will not pursue the obesity drug market, Chief Executive Joaquin Duato said, opting instead to build the company into what he described as the world's leading cancer company. The move sets J&J apart from rivals scrambling…

By Sofia Almeida2 min read
Share